16 July 2006
Intervet Introduces Continuum® Feline HCP Vaccine
The first and only proven 3-year feline vaccine against herpesvirus-1, calicivirus and panleukopenia
Intervet Inc., the world’s leading manufacturer of animal health vaccines, announced today the introduction of Continuum® Feline HCP vaccine with a 3-year duration of immunity against rhinotracheitis caused by herpesvirus-1 (FHV-1), calicivirus (FCV) and panleukopenia (FPV). Continuum Feline HCP is the first and only feline vaccine with proven 3-year protection against these three serious diseases. This new tool for veterinarians provides greater flexibility to customize feline vaccination protocols and streamline vaccine inventories.
Three-year revaccination intervals for core vaccines such as HCP are recommended by the American Association of Feline Practitioners (AAFP) and supported by the American College of Veterinary Internal Medicine (ACVIM) and the American Animal Hospital Association (AAHA).1<< P>
Safe, Effective Protection
With a non-adjuvanted formulation, Continuum Feline HCP provides long-term safety for feline patients 8 weeks of age and older and may reduce the risk of adverse events.2 Controlled, scientific challenge studies confirm both the safety and extended long-term efficacy of Continuum Feline HCP.
“As the 3-year vaccination expert, Intervet’s goal remains continuing to provide veterinarians with proven vaccines that allow them to better serve their patients,” explains Michael J. Coyne, VMD, PhD, market development manager for Intervet. “With the addition of Continuum Feline HCP, veterinarians now can implement 3-year HCP protocols with a USDA-approved vaccine. This eliminates the potential ethical and legal concerns that can arise when using annual vaccines at off-label intervals and allows for more flexible, customized feline patient care.”
“Veterinarians who may have felt uncomfortable using a vaccine that was not approved for a 3-year duration of immunity now can incorporate Continuum Feline HCP into their vaccination programs,” says Alice M. Wolf, DVM, DACVIM, DABVP, professor, small animal medicine, College of Veterinary Medicine, Texas A&M University. She explains that patients, clients and veterinarians can benefit from a 3-year vaccination protocol as a step in improved preventive care. “Employing a 3-year vaccination protocol is less expensive for the client,” she says. “That may allow investing in tools such as radiography and laboratory work that will help enhance a pet’s overall health and wellness.”
Challenge studies performed with Continuum Feline HCP confirmed 3-year HCP protection, with results for all three antigens meeting 9CFR challenge requirements. Study results included:
- Rhinotracheitis: Statistically significant reduction in virulent FRV-associated clinical signs (P=0.005)
- Calicivirus: 100 percent protection against oral ulcerations associated with FCV infection
- Panleukopenia: 100 percent protection against disease associated with virulent FPV challenge
Core Vaccination Guidelines
Vaccination against rhinotracheitis caused by herpesvirus-1, calicivirus infection and panleukopenia is considered essential and routine for all cats. Revaccination with Continuum Feline HCP every three years conforms to current vaccination guidelines from AAFP and other major veterinary groups. Vaccination protocols should always consider risk factors specific to your area and your patients, as well as state or county regulations. Core vaccinations are one component of an overall feline health program, which includes regularly scheduled veterinary visits for optimum care.
Additional Continuum Feline Vaccines
In addition to Continuum Feline HCP, the Continuum family of feline vaccines provides several others for triennial and annual vaccination options. Three-year feline vaccines include Continuum Feline HCP-R (rhinotracheitis virus, calicivirus, panleukopenia virus and rabies virus); Continuum Feline HC (rhinotracheitis virus and calicivirus); and Continuum Feline P (panleukopenia virus). Vaccines for annual vaccination include Continuum Feline Cp (Chlamydia psittaci) and Continuum Feline Bb (Bordetella bronchiseptica).
1 American Association of Feline Practitioners. 2000 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines. Available at: http://www.aafponline.org/resources/guidelines/vaccine.pdf. Accessed April 27, 2006.
2 Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc. 2005;227:1102-1108.
All trademarks are registered trademarks or trademarks of Intervet Inc. or an affiliate.
For more information about Continuum core vaccines, visit www.continuum3.com.